Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Mineralys Therapeutics, Inc.. The associated price target remains the same with $56.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matthew Caufield has given his Buy rating due to a combination of factors, most notably the FDA’s acceptance of Mineralys’ NDA for lorundrostat in hypertension with a December 22, 2026 PDUFA date, which materially advances the program toward potential commercialization. He views lorundrostat as a differentiated aldosterone synthase inhibitor that has repeatedly shown meaningful, double‑digit blood pressure reductions on top of standard therapy, with a safety and tolerability profile that supports use in uncontrolled and resistant hypertension, where a large share of patients still fail to achieve target blood pressure.
He also points to recent trial data in hypertensive patients with obstructive sleep apnea, where lorundrostat did not meet the primary sleep apnea endpoint but again produced clinically significant blood pressure reductions and maintained a favorable safety profile, including absence of concerning potassium elevations. In addition, KOL feedback suggests that the sizable U.S. population of uncontrolled hypertension patients can sustain multiple aldosterone synthase inhibitors, and cardiologists appear receptive to lorundrostat’s efficacy, dosing convenience, and manageable hyperkalemia risk, all of which underpin his Buy rating and $56 price target.
In another report released on March 13, Stifel Nicolaus also reiterated a Buy rating on the stock with a $52.00 price target.